Pfizer gives shareholders say on pay; Shire subpoenaed in U.S. marketing probe;

> Pfizer said its shareholders will have input on compensation for company executives starting in 2010. Release

> U.K. drug maker Shire has been subpoenaed by the U.S. authorities over the marketing of three bestselling drugs. Report

> Mead Johnson Nutrition sold $1.5 billion worth of debt in a three-part sale. Report

> Time Warner said Schering Plough Chief Executive Fred Hassan has been elected to its board. Report

> Allergan said quarterly profit rose 8 percent as sales of anti-wrinkle drug Botox rebounded and helped offset lower sales of medical devices. Report

> Three of Japan's top pharmaceutical companies reported profit gains following aggressive acquisitions, but the strong yen damped their earnings recovery. Report

> Fourteen drugmakers have accepted Ecuador's new policy of bypassing the patents on 2,000 drugs in order to produce them locally or buy cheaper versions elsewhere. Report

Biotech News

> It seems even Google-backed companies aren't immune to the economic crisis. Personal genetics company 23andMe has confirmed that its laying off an unspecified number of staffers. Article

> Continuing its plan to redesign itself as a biotech, Lilly announced that it's establishing an environmentally-friendly, 200-person biotech facility in San Diego. Article

> Amicus has terminated it pact with shire and cut 20 percent of its staff. Report

> One of China's key economic development groups has spawned 20 new venture capital funds to invest in the country's high tech sector--with biotechnology as a prime focus. Report

> Genta's stock took a nosedive yesterday on news that its lead drug Genasense, a Phase III candidate for melanoma, did not show a statistically significant benefit for its co-primary endpoint of progression-free survival. Article

And Finally ... Lifestyle changes are the best way to stave off development of Type 2 diabetes, according to a 10-year followup of an innovative trial to prevent the disease in high-risk groups. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.